版本:
中国

BRIEF-Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

April 17 Oncomed Pharmaceuticals Inc

* Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

* Oncomed Pharmaceuticals Inc - trial did not meet its primary endpoint of progression-free survival or secondary endpoints

* Also announces discontinuation of brontictuzumab Phase 1B study Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐